Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

NCT02581930 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

NIH

Sponsor class

Conditions

Metastatic Melanoma
Recurrent Cutaneous Melanoma
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacogenomic Study
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)